Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 2Other hematologic neoplasm 2Myeloid 2Classical hematology 2CNS 2Thoracic 1Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Influenza, Human 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Blood Specimen Collection 53Surveys and Questionnaires 30Drug Therapy 27Immunotherapy 25Surgical Procedures, Operative 22Carboplatin 22Nivolumab 21Immune Checkpoint Inhibitors 20pembrolizumab 18osimertinib 18atezolizumab 17Observation 17Radiotherapy 16Bevacizumab 15Cisplatin 14Afatinib 14Specimen Handling 13Gene Expression Profiling 13Erlotinib Hydrochloride 13lorlatinib 12Pemetrexed 12Magnetic Resonance Spectroscopy 11Ipilimumab 11Immunohistochemistry 11Biopsy 11durvalumab 10alectinib 10Paclitaxel 10Bronchoscopy 10Tomography, X-Ray Computed 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Influenza Vaccines × Thoracic × Clear all
NCT04355806 2020-04-21

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Shanghai Pulmonary Hospital, Shanghai, China

Unknown
160 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Influenza, Human

Data powered by HemOnc (CC BY 4.0) Colophon âš¡